These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8179963)

  • 21. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
    Peng H; Callison D; Li P; Burrell C
    Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication.
    Klimatcheva E; Planelles V; Day SL; Fulreader F; Renda MJ; Rosenblatt J
    Mol Ther; 2001 Jun; 3(6):928-39. PubMed ID: 11407907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of chimeric neo-Rev response element sequences interferes with Rev-dependent HIV-1 Gag expression.
    Zimmermann K; Weber S; Dobrovnik M; Hauber J; Böhnlein E
    Hum Gene Ther; 1992 Apr; 3(2):155-61. PubMed ID: 1391035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene.
    Harrison GS; Long CJ; Curiel TJ; Maxwell F; Maxwell IH
    Hum Gene Ther; 1992 Oct; 3(5):461-9. PubMed ID: 1329991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
    Mautino MR; Keiser N; Morgan RA
    J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Murine retrovirus vector expressing env gene of human immunodeficiency virus type 1 (HIV-1)].
    Kimura T; Karn J
    Uirusu; 1991 Dec; 41(2):85-94. PubMed ID: 1810088
    [No Abstract]   [Full Text] [Related]  

  • 27. High expression of exogenous cDNAs directed by HIV-1 long terminal repeat in human cells constitutively producing HIV-1 tat and adenovirus E1A/E1B.
    Negrini M; Rimessi P; Sabbioni S; Caputo A; Balboni PG; Gualandri R; Manservigi R; Grossi MP; Barbanti-Brodano G
    Biotechniques; 1991 Mar; 10(3):344-53. PubMed ID: 1829615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological importance and cooperativity of HIV-1 regulatory gene splice acceptors.
    Riggs NL; Little SJ; Richman DD; Guatelli JC
    Virology; 1994 Jul; 202(1):264-71. PubMed ID: 8009838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Propagation of SIV vectors by genetic complementation with a heterologous env gene.
    Rizvi TA; Panganiban AT
    AIDS Res Hum Retroviruses; 1992 Jan; 8(1):89-95. PubMed ID: 1310604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
    Mautino MR; Morgan RA
    Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient antigen presentation to cytotoxic T lymphocytes by cells transduced with a retroviral vector expressing the HIV-1 Nef protein.
    Robertson MN; Buseyne F; Schwartz O; Rivière Y
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1217-23. PubMed ID: 7511396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Murine retroviral vector that induces long-term expression of HIV-1 envelope protein.
    Fujita K; Maldarelli F; Purcell DF; Silver J
    J Virol Methods; 1994 Dec; 50(1-3):293-311. PubMed ID: 7714053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping.
    Asparuhova MB; Marti G; Liu S; Serhan F; Trono D; Schümperli D
    J Gene Med; 2007 May; 9(5):323-34. PubMed ID: 17474072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safe and efficient ecotropic and amphotropic packaging lines for use in gene transfer experiments.
    Markowitz DG; Goff SP; Bank A
    Trans Assoc Am Physicians; 1988; 101():212-8. PubMed ID: 3077729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the South African HIV type 1 subtype C complete 5' long terminal repeat, nef, and regulatory genes.
    Scriba TJ; de Villiers T; Treurnicht FK; zur Megede J; Barnett SW; Engelbrecht S; van Rensburg EJ
    AIDS Res Hum Retroviruses; 2002 Jan; 18(2):149-59. PubMed ID: 11839148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction and use of a safe and efficient amphotropic packaging cell line.
    Markowitz D; Goff S; Bank A
    Virology; 1988 Dec; 167(2):400-6. PubMed ID: 2462307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human immunodeficiency virus-1 tat- and tat/nef-defective genomes containing HIV-regulated diphtheria toxin A chain gene inhibit HIV replication.
    Brdar B; Matulić M; Rubelj I; Ivanković M; Reich E
    Croat Med J; 2002 Oct; 43(5):591-7. PubMed ID: 12402403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.
    Junker U; Böhnlein E; Veres G
    Gene Ther; 1995 Nov; 2(9):639-46. PubMed ID: 8548553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic modification of human peripheral blood lymphocytes with a transdominant negative form of Rev: safety and toxicity.
    Fox BA; Woffendin C; Yang ZY; San H; Ranga U; Gordon D; Osterholzer J; Nabel GJ
    Hum Gene Ther; 1995 Aug; 6(8):997-1004. PubMed ID: 7578421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.